Advanced imaging modalities, such as multiparametric magnetic resonance imaging (mpMRI) and prostate-specific membrane antigen (PSMA) positron emission tomography (PET), have revolutionized lesion localization in recurrent PCa, improving patient selection by distinguishing between local and systemic disease and enhancing intraprostatic tumor detection and localization [1], [14], [15], [16]. This evidence concerns the gene FOLH1 and neoplasm.